Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 12,609 · FY2024 18,890 — 3-yr total 31,499
Pharmaceutical importer/distributor active in the Georgian market.
| Line item | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Total Revenue | 775 | 34,191 | 48,230 | 65,941 | +339.8% |
| Total COGS | 674 | 18,932 | 19,376 | 24,855 | +232.9% |
| Gross Profit | 101 | 15,259 | 28,854 | 41,086 | nmf |
| Gross Margin | 13.1% | 44.6% | 59.8% | 62.3% | |
| 119 | 3,245 | 5,993 | 7,024 | +289.3% | |
| EBITDA | 18 | 12,014 | 22,861 | 34,062 | nmf |
| EBITDA Margin | 2.3% | 35.1% | 47.4% | 51.7% | |
| Total D&A | 31 | 27 | 83 | 290 | +109.7% |
| EBIT / Operating Income | 49 | 11,987 | 22,778 | 33,772 | nmf |
| 14 | 130 | 254 | 229 | +155.6% | |
| Profit Before Tax | 63 | 12,117 | 22,524 | 33,543 | nmf |
| Total Income Tax | 13 | 59 | 239 | 293 | +180.7% |
| Net Profit / (Loss) | 76 | 12,058 | 22,285 | 33,250 | nmf |
| Net Margin | 9.8% | 35.3% | 46.2% | 50.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →